sFlt-1 in Chronic Kidney Disease: Friend or Foe?

被引：6
|
作者：
Matsui, Masaru [1 ,2 ]
Onoue, Kenji [3 ]
Saito, Yoshihiko [4 ]
机构：
[1] Nara Prefecture Gen Med Ctr, Dept Nephrol, 2-897-5 Shichijo Nishimachi, Nara 6308581, Japan
[2] Nara Med Univ, Dept Nephrol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan
[3] Nara Med Univ, Dept Cardiol, 840 Shijo Cho, Kashihara, Nara 6348521, Japan
[4] Nara Prefecture Seiwa Med Ctr, 1-14-16 Mimuro,Sango Cho, Kashihara, Nara 6360802, Japan
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 22期
关键词：
PlGF; sFlt-1; cardiorenal connection; ENDOTHELIAL-GROWTH-FACTOR; TYROSINE KINASE-1; CARDIOVASCULAR EVENTS; FACTOR EXPRESSION; RECEPTOR; VEGF; CONTRIBUTES; ANGIOGENESIS; PROGRESSION; PLAQUES;
D O I：
10.3390/ijms232214187
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Placental growth factor (PlGF) and its receptor, fms-like tyrosine kinase-1 (Flt-1), are important regulators involved in angiogenesis, atherogenesis, and inflammation. This review article focuses on the function of PlGF/Flt-1 signaling and its regulation by soluble Flt-1 (sFlt-1) in chronic kidney disease (CKD). Elevation of circulating sFlt-1 and downregulation of sFlt-1 in the vascular endothelium by uremic toxins and oxidative stress both exacerbate heart failure and atherosclerosis. Circulating sFlt-1 is inconsistent with sFlt-1 synthesis, because levels of matrix-bound sFlt-1 are much higher than those of circulating sFlt-1, as verified by a heparin loading test, and are drastically reduced in CKD.
引用
收藏
页数：13
相关论文
共 50 条
  • [1] Vegetarian Diet in Chronic Kidney Disease-A Friend or Foe
    Gluba-Brzozka, Anna
    Franczyk, Beata
    Rysz, Jacek
    [J]. NUTRIENTS, 2017, 9 (04)
  • [2] The role of statins in chronic kidney disease (CKD): Friend or foe?
    Kassimatis, Theodoros I.
    Konstantinopoulos, Panagiotis A.
    [J]. PHARMACOLOGY & THERAPEUTICS, 2009, 122 (03) : 312 - 323
  • [3] Hypoxia induced Factor in chronic Kidney Disease: Friend or Foe?
    Li, Weiying
    Zhao, Yuliang
    Fu, Ping
    [J]. FRONTIERS IN MEDICINE, 2018, 4
  • [4] The Aryl Hydrocarbon Receptor in Chronic Kidney Disease: Friend or Foe?
    Mo, Yenan
    Lu, Zhaoyu
    Wang, Lixin
    Ji, Chunlan
    Zou, Chuan
    Liu, Xusheng
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [5] KETODIET IN ADVANCED DIABETIC CHRONIC KIDNEY DISEASE-FRIEND OR FOE?
    Teodoru, Ileana
    Rusu, Emilia
    Posea, Mihaela
    Radulian, Gabriela
    [J]. INTERDISCIPLINARY APPROACHES IN DIABETIC CHRONIC KIDNEY DISEASE, 2015, : 301 - 307
  • [6] A Friend or a Foe? Bariatric Surgery in Chronic Kidney Disease: A Case Report
    Bagai, Sahil
    Bansal, Bhavna
    Malik, Vipra
    Prasad, Pallavi
    Khullar, Dinesh
    [J]. CASE REPORTS IN NEPHROLOGY AND DIALYSIS, 2022, 12 (03): : 207 - 211
  • [7] Metabolic acidosis of chronic kidney disease and subclinical cardiovascular disease markers Friend or foe?
    Capusa, Cristina
    Stefan, Gabriel
    Stancu, Simona
    Lipan, Mariana
    Tsur, Lilach Daniel
    Mircescu, Gabriel
    [J]. MEDICINE, 2017, 96 (47)
  • [8] Angiotensin-(1-7) and Kidney Disease: Friend or Foe
    Velkoska, Elena
    Patel, Sheila K.
    Burrell, Louise M.
    [J]. HYPERTENSION, 2013, 62 (03) : E10 - E10
  • [9] Response to Angiotensin-(1-7) and Kidney Disease: Friend or Foe
    Li, Peng
    Sun, Hai-Jian
    Cui, Bai-Ping
    Zhou, Ye-Bo
    Han, Ying
    [J]. HYPERTENSION, 2013, 62 (03) : E11 - E11
  • [10] Significance of the sFlt-1/PIGF Ratio and the uterine Doppler for the Prediction of the perinatal and maternal Outcome in Pregnant Women with chronic Kidney Disease
    Karge, A.
    Beckert, L.
    Moog, P.
    Haller, B.
    Ortiz, J.
    Abel, K.
    Lobmaier, S.
    Kuschel, B.
    Graupner, O.
    [J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (10) : E126 - E126
12345